Iron status in chronic inflammatory disease: therapeutic implications

Area of Science:

• Hematology
• Internal Medicine
• Pathophysiology

Background:

• Anemia of inflammation (AI) is a prevalent condition in patients with chronic inflammatory disorders like CKD, heart failure, and IBD.
• It is frequently associated with iron deficiency (ID), complicating disease recovery.
• The pathophysiology involves complex iron dysregulation, leading to hypoferremia and restricted erythropoiesis.

Purpose of the Study:

• To review the pathophysiology of iron dysregulation in anemia of inflammation.
• To discuss current and novel therapeutic strategies for managing AI and associated iron deficiency.
• To highlight the limitations of oral iron and the advantages of intravenous iron in these patients.

Main Methods:

• Literature review of anemia of inflammation pathophysiology.
• Analysis of current treatment options including iron replacement, ESAs, and transfusions.
• Exploration of emerging therapeutic targets such as hepcidin and HIF pathways.

Main Results:

• AI is characterized by hypoferremia and iron-restricted erythropoiesis, often with normal or elevated ferritin.
• Oral iron therapy shows limitations in AI due to impaired gut absorption in chronic inflammation.
• Intravenous iron administration bypasses absorption issues and is a valuable option.

Conclusions:

• Understanding AI pathophysiology is crucial for effective management.
• Intravenous iron is a preferred route for iron repletion in AI patients with inflammatory conditions.
• Novel therapies targeting hepcidin and HIF pathways show promise but require further human studies.